Effect of Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion on Parkinson's Disease–Related Pain: A 6‐Month Real‐World Longitudinal Study

Abstract Background Foslevodopa/foscarbidopa (LDp/CDp) infusion may reduce PD‐related pain; however, its effects on different pain manifestations remain unclear. Objective The aim was to evaluate longitudinal changes in overall and domain‐specific PD‐related pain after LDp/CDp infusion. Methods Twenty‐six patients with advanced PD initiating LDp/CDp infusion underwent evaluation at baseline (T0) and 6 months (T1). Pain was assessed using the King's Parkinson's Disease Pain Scale (KPPS). Secondary outcomes included motor complications, quality of life (QoL), dopaminergic treatment burden, and pain–motor correlations. Results At T1, KPPS total score decreased (9.6 ± 6.5 vs. 2.7 ± 4.7, P  P  = 0.01), fluctuation‐related ( P  P  P  P  = 0.04). QoL improved ( P  = 0.006), whereas dopaminergic treatment burden was unchanged. Conclusions LDp/CDp infusion improved PD‐related pain, particularly chronic, fluctuation‐related, and nocturnal pain, with a parallel improvement in QoL, suggesting benefits beyond motor complication management.